In the era of successful immunotherapy, while non-oncogene addicted advanced NSCLC obtains a great survival benefit, the effectiveness of immunotherapy in EGFR-mutated NSCLC appears disappointing. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.